Search

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more

EHA Statement of Solidarity with local communities in Türkiye and Syria

The European Hematology Association (EHA) is deeply concerned about the situation in southern Türkiye and northern Syria: Monday's earthquakes and aftershocks have killed thousands of people and destroyed innumerable buildings, while freezing temperatures and damaged roads are hampering rescue efforts.

Read more

Meet YoungEHA leaders Verena and Heiko

By Dr. Fabienne Lucas, MD PhD, YoungEHA Committee.

Read more

Community and Stakeholder Committee call for interest

The Community and Stakeholder Committee (CSC) serves as an advisory body to the EHA Board and works closely with the EHA Office and other committees.

Read more

Proposal for an EU Regulation on Clinical Trials: A joint statement from non-commercial and commercial organisations

This statement outlines the areas of agreement within the health and research communities on where the Regulation will improve the research environment. Aspects of the Regulation that could be improved to further support clinical research are also highlighted.

Read more

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

 

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more